Gill David M, Agarwal Neeraj
Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT.
Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT.
Urol Oncol. 2017 Dec;35(12):676-677. doi: 10.1016/j.urolonc.2017.09.023. Epub 2017 Oct 18.
The recent resurgence of immunotherapy has transformed the therapeutic field of advanced urologic cancers. In this seminars issue, we evaluate the role of emerging and recently approved immunotherapeutic agents in advanced prostate, urothelial, and renal cell carcinoma. In each of these fields, we discuss recent regulatory approvals as well as promising ongoing clinical trials. Finally, we discuss incidence and management of immune related adverse events specifically associated with PD-1/PD-L1 inhibitors.
免疫疗法最近的复兴改变了晚期泌尿系统癌症的治疗领域。在本期研讨会特刊中，我们评估了新兴的和最近获批的免疫治疗药物在晚期前列腺癌、尿路上皮癌和肾细胞癌中的作用。在这些领域中的每一个，我们都讨论了最近的监管批准情况以及正在进行的有前景的临床试验。最后，我们讨论了与PD-1/PD-L1抑制剂特别相关的免疫相关不良事件的发生率和管理。
